Pascale Louis-Plence

List of Publications by Year
in descending order

61 papers	4,227 citations	270111 25 h-index	286692 43 g-index
61 all docs	61 docs citations	61 times ranked	6253 citing authors

#	Article	IF	Citations
1	Differential Accumulation and Activation of Monocyte and Dendritic Cell Subsets in Inflamed Synovial Fluid Discriminates Between Juvenile Idiopathic Arthritis and Septic Arthritis. Frontiers in Immunology, 2020, 11, 1716.	2.2	13
2	P014/O04â€...Phenotypic heterogeneity of regulatory T cells in rheumatoid arthritis. , 2019, , .		0
3	PolyoxidoniumÂ® Activates Cytotoxic Lymphocyte Responses Through Dendritic Cell Maturation: Clinical Effects in Breast Cancer. Frontiers in Immunology, 2019, 10, 2693.	2.2	21
4	Arthritis sensory and motor scale: predicting functional deficits from the clinical score in collagen-induced arthritis. Arthritis Research and Therapy, 2019, 21, 264.	1.6	7
5	Injection of Adipose-Derived Stromal Cells in the Knee of Patients with Severe Osteoarthritis has a Systemic Effect and Promotes an Anti-Inflammatory Phenotype of Circulating Immune Cells. Theranostics, 2018, 8, 5519-5528.	4.6	51
6	A new autoinflammatory and autoimmune syndrome associated with NLRP1 mutations: NAIAD (NLRP1-associated autoinflammation with arthritis and dyskeratosis). Annals of the Rheumatic Diseases, 2017, 76, 1191-1198.	0.5	181
7	07.16â€...Nlrp1 mutations cause autoinflammatory diseases in human: implication of the nlrp1 inflammasome?. , 2017, , .		0
8	Cellular senescence impact on immune cell fate and function. Aging Cell, 2016, 15, 400-406.	3.0	104
9	Nonclassical CD4+CD49b+ Regulatory T Cells as a Better Alternative to Conventional CD4+CD25+ T Cells To Dampen Arthritis Severity. Journal of Immunology, 2016, 196, 298-309.	0.4	15
10	Systemic LPS Translocation Activates Cross-Presenting Dendritic Cells but Is Dispensable for the Breakdown of CD8+ T Cell Peripheral Tolerance in Irradiated Mice. PLoS ONE, 2015, 10, e0130041.	1.1	4
11	A6.5â€...Versatile polyion complex micelles for peptide and sirna vectorization to engineer tolerogenic dendritic cells. Annals of the Rheumatic Diseases, 2015, 74, A57.1-A57.	0.5	0
12	Versatile polyion complex micelles for peptide and siRNA vectorization to engineer tolerogenic dendritic cells. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 92, 216-227.	2.0	5
13	A8.26â€...Inducible IL-10 secreting CD49b+Treg cells as cell based-therapy for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, A86.2-A86.	0.5	2
14	Reply. Arthritis and Rheumatology, 2014, 66, 2640-2641.	2.9	1
15	Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis. Arthritis Research and Therapy, 2014, 16, R115.	1.6	52
16	Interleukinâ€6 Receptor Blockade Enhances CD39+ Regulatory T Cell Development in Rheumatoid Arthritis and in Experimental Arthritis. Arthritis and Rheumatology, 2014, 66, 273-283.	2.9	96
17	AB0053â€...Increased Frequency of Plasmacytoid Dentritic Cells in Rheumatoid Arthritis Patients in Response to IL-6R Blockade. Annals of the Rheumatic Diseases, 2014, 73, 821.2-821.	0.5	0
18	<scp>DX</scp>5⁺<scp>CD</scp>4⁺<scp>T</scp> cells modulate <scp>CD</scp>4⁺<scp>T</scp>â€cell response via inhibition of <scp>IL</scp>â€12 production by <scp>DC</scp>s. European Journal of Immunology, 2013, 43, 439-446.	1.6	4

#	Article	IF	Citations
19	The role of miR-155 in regulatory T cells and rheumatoid arthritis. Clinical Immunology, 2013, 148, 56-65.	1.4	22
20	A3.10â€…IL-6 Receptor Blockade Enhances CD39+ Regulatory T-Cell Development in Rheumatoid Arthritis and in Experimental Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A16.3-A17.	0.5	0
21	A3.6â€…Comparative Analysis of the Therapeutic Potential of Inducible Treg Cell PopulAtions in Experimental Model of Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A15.2-A15.	0.5	0
22	Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis. Annals of the Rheumatic Diseases, 2013, 72, 1717-1724.	0.5	38
23	OP0220â€…Innovative anti-inflammatory strategy in arthritis using PBEF sirna-mediated silencing in LY-6CHIGH monocytes. Annals of the Rheumatic Diseases, 2013, 71, 130.2-130.	0.5	0
24	RNAi-mediated gene silencing in inflammatory monocytes for efficient immuno-intervention in experimental arthritis. Annals of the Rheumatic Diseases, 2012, 71, A75.1-A75.	0.5	0
25	Immunosuppressive DX5+ T cells are potent inhibitors of Th-1 responses via modulation of DCs. Annals of the Rheumatic Diseases, 2012, 71, A17.2-A18.	0.5	0
26	NAMPT/Visfatin expression by inflammatory monocytes mediates arthritis pathogenesis by promoting IL-17â€“producing T cells. Journal of Translational Medicine, 2012, 10, .	1.8	0
27	Inducible Treg cell populations as cell based-therapy for rheumatoid arthritis. Journal of Translational Medicine, 2012, 10, .	1.8	0
28	Comparative analysis of the therapeutic potential of two inducible Treg cell populations in experimental model of arthritis. Annals of the Rheumatic Diseases, 2012, 71, A35.2-A36.	0.5	0
29	Development of tripartite polyion micelles for efficient peptide delivery into dendritic cells without altering their plasticity. Journal of Controlled Release, 2011, 154, 156-163.	4.8	21
30	Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis. Journal of Translational Medicine, 2011, 9, .	1.8	0
31	Targeted delivery to inflammatory monocytes for efficient RNAi-mediated immuno-intervention in auto-immune arthritis. Journal of Translational Medicine, 2011, 9, P38.	1.8	0
32	Rapamycin-induced alteration of the DC maturation process sustains their capacity to induce regulatory T cells. Annals of the Rheumatic Diseases, 2011, 70, A70-A70.	0.5	1
33	Longitudinal immunomonitoring following tocilizumab in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, A86-A86.	0.5	0
34	Injection of antigen-specific regulatory Tr1 lymphocytes protects mice from severe collagen-induced arthritis. Annals of the Rheumatic Diseases, 2011, 70, A69-A69.	0.5	0
35	DX5⁺CD4⁺ T cells modulate cytokine production by CD4⁺ T cells towards ILâ€10 via the production of ILâ€4. European Journal of Immunology, 2010, 40, 2731-2740.	1.6	5
36	Adoptive transfer of IL-10-secreting CD4+CD49b+ regulatory T cells suppresses ongoing arthritis. Journal of Autoimmunity, 2010, 34, 390-399.	3.0	27

#	Article	IF	Citations
37	DCâ€induced CD8⁺ Tâ€cell response is inhibited by MHC class Iiâ€dependent DX5⁺CD4⁺ Treg. European Journal of Immunology, 2009, 39, 1765-1773.	1.6	9
38	The control of dendritic cell maturation by pH-sensitive polyion complex micelles. Biomaterials, 2009, 30, 233-241.	5.7	40
39	Tripartite siRNA micelles as controlled delivery systems for primary dendritic cells. Drug Development and Industrial Pharmacy, 2009, 35, 950-958.	0.9	10
40	Antitumoral Activity and Osteogenic Potential of Mesenchymal Stem Cells Expressing the Urokinase-Type Plasminogen Antagonist Amino-Terminal Fragment in a Murine Model of Osteolytic Tumor. Stem Cells, 2008, 26, 2981-2990.	1.4	40
41	Transient down-regulation of cbfa1/Runx2 by RNA interference in murine C3H10T1/2 mesenchymal stromal cells delays in vitro and in vivo osteogenesis, but does not overtly affect chondrogenesis. Experimental Cell Research, 2008, 314, 1495-1506.	1.2	28
42	Immunomodulatory Dendritic Cells Inhibit Th1 Responses and Arthritis via Different Mechanisms. Journal of Immunology, 2007, 179, 1506-1515.	0.4	86
43	Micro-CT combined with bioluminescence imaging: A dynamic approach to detect early tumorâ€“bone interaction in a tumor osteolysis murine model. Bone, 2007, 40, 1032-1040.	1.4	46
44	Microenvironmental changes during differentiation of mesenchymal stem cells towards chondrocytes. Arthritis Research and Therapy, 2007, 9, R33.	1.6	149
45	Mesenchymal Stem Cells Inhibit the Differentiation of Dendritic Cells Through an Interleukin-6-Dependent Mechanism. Stem Cells, 2007, 25, 2025-2032.	1.4	562
46	Earlier Onset of Syngeneic Tumors in the Presence of Mesenchymal Stem Cells. Transplantation, 2006, 82, 1060-1066.	0.5	122
47	Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor Î± in experimental arthritis. Arthritis and Rheumatism, 2006, 54, 1867-1877.	6.7	175
48	A comparative study on intra-articular versus systemic gene electrotransfer in experimental arthritis. Journal of Gene Medicine, 2006, 8, 1027-1036.	1.4	32
49	Immature Dendritic Cells Suppress Collagen-Induced Arthritis by In Vivo Expansion of CD49b+ Regulatory T Cells. Journal of Immunology, 2006, 177, 3806-3813.	0.4	94
50	87. Efficient Delivery of Small Interfering RNA Targeting Pro_Inflammatory Cytokines in Experimental Arthritis. Molecular Therapy, 2006, 13, S36.	3.7	0
51	1067. Amelioration of Arthritis after Local Delivery of an Adeno-Associated Virus Type 6 Expressing a TNF-Blocking Agent under a Disease-Inducible Promoter. Molecular Therapy, 2006, 13, S409.	3.7	0
52	Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor Î± in collagen-induced arthritis. Arthritis and Rheumatism, 2005, 52, 1595-1603.	6.7	344
53	Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells. Arthritis Research and Therapy, 2005, 7, R1304.	1.6	178
54	Antigen-specific immunomodulation of collagen-induced arthritis with tumor necrosis factor-stimulated dendritic cells. Arthritis and Rheumatism, 2004, 50, 3354-3364.	6.7	63

#	Article	IF	Citations
55	Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood, 2003, 102, 3837-3844.	0.6	1,079
56	Tetracycline Transcriptional Silencer Tightly Controls Transgene Expression AfterIn VivoIntramuscular Electrotransfer: Application to Interleukin 10 Therapy in Experimental Arthritis. Human Gene Therapy, 2002, 13, 2161-2172.	1.4	67
57	Specific overexpression of rheumatoid arthritis-associated HLA-DR alleles and presentation of low-affinity peptides. Arthritis and Rheumatism, 2001, 44, 1281-1292.	6.7	13
58	The Down-Regulation of HLA-DM Gene Expression in Rheumatoid Arthritis Is Not Related to Their Promoter Polymorphism. Journal of Immunology, 2000, 165, 4861-4869.	0.4	28
59	CREB Regulates MHC Class II Expression in a CIITA-Dependent Manner. Immunity, 1999, 10, 143-151.	6.6	170
60	RFX-B Is the Gene Responsible for the Most Common Cause of the Bare Lymphocyte Syndrome, an MHC Class II Immunodeficiency. Immunity, 1999, 10, 153-162.	6.6	154
61	Polymorphism in the regulatory region of HLA-DRB genes correlating with haplotype evolution. Immunogenetics, 1993, 38, 21-26.	1.2	68